Liposomal Nicotinamide Riboside (NR) is a precursor to Nicotinamide Adenine Dinucleotide (NAD+), a critical coenzyme for cellular metabolism and DNA repair. The liposomal formulation encapsulates NR in lipid spheres, aiming to protect it from degradation in the digestive tract and enhance its absorption and bioavailability compared to standard NR formulations. By increasing systemic NAD+ levels, it may support mitochondrial function and activate sirtuins, proteins involved in cellular health and longevity.
Verdict
A promising but unproven strategy for boosting cellular NAD+ via enhanced delivery.
HEALTHSPAN IMPACT
Moderate
RISK LEVEL
Low
EVIDENCE GRADE
B
MONTHLY COST
$45 - $80
Protocol
- Typical daily doses range from 250 mg to 500 mg, taken once daily.
- Often taken in the morning to align with circadian rhythms of NAD+ production.
Flags
- Liposomal formulations may significantly increase bioavailability, warranting caution with dosage compared to standard NR.
- Some preclinical studies raise concerns that high NAD+ levels could potentially fuel certain cancers, though human data is lacking.
- Common side effects include mild nausea, fatigue, headaches, or itching.